NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
157 trialsNCT07481058 2026-03-18
A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06493019 2026-03-12
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07039162 2026-02-27
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
China Medical University Hospital
Phase 2 Recruiting
NCT05753306 2026-02-25
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Mayo Clinic
Phase 2 Recruiting
NCT06519591 2026-02-18
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
Ruijin Hospital
Phase 2 Recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT07139951 2025-12-31
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence
Mayo Clinic
Phase 2 Enrolling by invitation
NCT07304258 2025-12-26
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
Hebei Medical University
Phase 2 Not yet recruiting
NCT02297217 2025-12-16
PaRCUS
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT04209686 2025-12-03
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT06251973 2025-12-02
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT01142388 2025-11-25
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05189730 2025-11-20
ETNT
Sichuan Cancer Hospital and Research Institute
Phase 2 Active not recruiting
NCT04175912 2025-11-17
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04656041 2025-11-14
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
Phase 2 Recruiting
NCT06143748 2025-09-17
EC-CRT-006
Sun Yat-sen University
Phase 2 Active not recruiting
NCT03110926 2025-09-12
Induction Chemotherapy for Locally Advanced Esophageal Cancer
University of Rochester
Phase 2 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04069273 2025-07-31
SEQUEL
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07028424 2025-07-01
PANORAMIX
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT07045805 2025-07-01
Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT05311176 2025-05-11
nextHERIZON
Imugene Limited
Phase 2 Terminated
NCT06965829 2025-05-11
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06637163 2025-04-17
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06914687 2025-04-06
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT05185947 2025-03-07
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04804696 2025-02-21
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Terminated
NCT04034251 2025-02-03
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT06745193 2024-12-20
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer
Peking University
Phase 2 Not yet recruiting
NCT05520619 2024-11-18
EC-CRT-002
Sun Yat-sen University
Phase 2 Active not recruiting
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05628610 2024-08-13
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT03760822 2024-07-08
SOCRATE
Federation Francophone de Cancerologie Digestive
Phase 2 Active not recruiting
NCT03077685 2024-06-24
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
NanOlogy, LLC
Phase 2 Completed
NCT06084897 2024-06-14
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06415669 2024-05-29
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT05490719 2024-05-21
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT02931890 2024-05-02
CRITICS-II
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT03579784 2024-04-19
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Seoul National University Hospital
Phase 2 Active not recruiting
NCT04660760 2024-04-01
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT05905887 2024-02-28
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
Phase 2 Recruiting
NCT04694183 2024-02-07
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Phase 2 Completed
NCT06222944 2024-01-25
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Peking University
Phase 2 Not yet recruiting
NCT04568200 2024-01-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT02916511 2023-12-22
ESO-Shanghai9
Fudan University
Phase 2 Completed